- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Selumetinib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Chicago, Illinois • Chapel Hill, North Carolina + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 10,858
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms
- Interventions
- BAY79-4620
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • San Antonio, Texas
- Conditions
- Atrophy, Geographic
- Interventions
- GSK933776, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more
- Conditions
- Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
- Interventions
- ECMO support, PROSpect protocolized therapies
- Device · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 14 Days to 20 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
- Conditions
- Cryptogenic Symptomatic Transient Ischemic Attack, Cryptogenic Ischemic Stroke
- Interventions
- Reveal® XT Insertable Cardiac Monitor
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 19
- States / cities
- Mountain View, California • Denver, Colorado • Chicago, Illinois + 15 more
- Conditions
- Obesity, Overweight
- Interventions
- Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, Ancillary therapy
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Carmichael, California + 31 more
- Conditions
- Myeloma Multiple
- Interventions
- Descartes 08
- Biological
- Lead sponsor
- Cartesian Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Orange, California • Nashville, Tennessee
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
- Interventions
- Health Education Program, Weight Loss Intervention
- Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2030
- U.S. locations
- 1464
- States / cities
- Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
- Interventions
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
- Drug · Combination Product
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 31
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 25 more
- Conditions
- Metabolic Syndrome
- Interventions
- Sildenafil citrate, Placebo Oral Capsule
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Psoriasis
- Interventions
- adalimumab
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Buckner 13075 PI, Alabama • Scottsdale, Arizona + 57 more
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
- Interventions
- Clinical Trial Matching
- Other
- Lead sponsor
- Massive Bio, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2040
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more
- Conditions
- Acute Kidney Injury
- Interventions
- Medication reconciliation, Blood Pressure Management
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Pancreatic Neoplasms, Metastases, Neoplasm
- Interventions
- GEMZAR, ALIMTA
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 40
- States / cities
- Huntsville, Alabama • Fountain Valley, California • Fullerton, California + 37 more
- Conditions
- Crohn's Disease, Complex Perianal Fistula
- Interventions
- Placebo, Darvadstrocel
- Other · Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 22
- States / cities
- San Francisco, California • West Hollywood, California • New Haven, Connecticut + 17 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Human Regular U-500 Insulin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 35
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
- Conditions
- West Nile Fever Encephalitis
- Interventions
- WN/DEN4-3'delta30, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Nashville, Tennessee
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Acyclovir
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 11 more
- Conditions
- Hemophilia A
- Interventions
- ReFacto AF, B-Domain deleted Recombinant Factor VIII, BDDrFVIII
- Genetic
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Sacramento, California • San Diego, California + 18 more
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
- Interventions
- STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (RP2D), STX-721/PFL-721 (Escalated) with platinum-based chemotherapy, STX-721/PFL-721 with platinum-based chemotherapy
- Drug
- Lead sponsor
- Pierre Fabre Medicament
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Duarte, California • Huntington Beach, California • Irvine, California + 6 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 78
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Urothelial Cancer
- Interventions
- Erdafitinib, Midazolam, Metformin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 25
- States / cities
- Sedona, Arizona • Los Angeles, California • Orange, California + 22 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- CAB-AXL-ADC, PD-1 inhibitor
- Biological
- Lead sponsor
- BioAtla, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 32
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 26 more
- Conditions
- Bronchiectasis, Bronchiectasis With Acute Exacerbation
- Interventions
- High Frequency Chest Wall Oscillation, Oscillating Positive Expiratory Pressure (OPEP)
- Device
- Lead sponsor
- Hill-Rom
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- New York, New York • Nashville, Tennessee • Tyler, Texas